首页> 美国卫生研究院文献>BMJ Open Access >Original article: Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world clinical practice HCV-TARGET study

【2h】

Original article: Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world clinical practice HCV-TARGET study

机译：原始文章：索非布韦联合利巴韦林治疗HCV基因型2型感染的有效性和安全性：实际临床研究HCV-TARGET研究的结果

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

ObjectiveDue to a high efficacy in clinical trials, sofosbuvir (SOF) and ribavirin (RBV) for 12 or 16 weeks is recommended for treatment of patients with HCV genotype (GT) 2 infection. We investigated safety and effectiveness of these regimens for GT2 in HCV-TARGET participants.

机译：目的由于在临床试验中具有较高的疗效，因此建议将索非布韦（SOF）和利巴韦林（RBV）治疗12或16周，以治疗HCV基因型（GT）2感染的患者。我们在HCV-TARGET参与者中研究了GT2方案的安全性和有效性。

著录项

期刊名称 BMJ Open Access
作者
Tania M Welzel; David R Nelson; Giuseppe Morelli; Adrian Di Bisceglie; Rajender K Reddy; Alexander Kuo; Joseph K Lim; Jama Darling; Paul Pockros; Joseph S Galati; Lynn M Frazier; Saleh Alqahtani; Mark S Sulkowski; Monika Vainorius; Lucy Akushevich; Michael W Fried; Stefan Zeuzem;
展开▼
作者单位

展开▼
年(卷),期 -1(66),10
年度 -1
页码 1844–1852
总页数 9
原文格式 PDF
正文语种
中图分类
关键词
HEPATITIS C GENOTYPE CLINICAL TRIALS;

机译：丙型肝炎;基因型;临床试验;

相似文献

外文文献
中文文献
专利

1. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study [J] . Welzel Tania M., Nelson David R., Morelli Giuseppe, Gut: Journal of the British Society of Gastroenterology . 2017,第10期

机译：Sofosbuvir Plus利巴韦林治疗HCV基因型2感染的有效性和安全性：现实世界的结果，临床实践HCV-靶研究
2. Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study [J] . Feld Jordan J., Maan Raoel, Zeuzem Stefan, Clinical infectious diseases . 2016,第6期

机译：基于Sofosbuvir的方案对慢性HCV基因型3感染的有效性和安全性：HCV-TARGET研究的结果
3. Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study [J] . Landis Charles S., Sulkowski Mark S., Reau Nancy, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：Velpatasvir和Sofosbuvir的治疗方案治疗HCV基因型的安全性和有效性：HCV-靶研究结果
4. HCV-related Factors but not HIV-Related Factors at Baseline Predict the Response to Treatment With Peginterferon alfa-2a (40KD) (PEGASYS) Plus Ribavirin (COPEGUS) in Patients With HCV/HIV Co-infection: Predictor Analysis From the APRICOT Study [C] . D. Cooper, F.J. Torriani, M. Rodriguez Torres International AIDS Conference . 2004

机译：HCV相关因素但基线上没有艾滋病毒相关因素预测与HCV / HIV共感染患者的Peginterferon Alfa-2a（40kd）（Pegasys）（Pegasys）加利巴韦林（Copegus）对治疗的反应：来自杏研究的预测因素分析
5. The Effectiveness of Virtual Clinical Simulation on the Transferability of Clinical Nursing Skills to Practice: A Qualitative Interview Study. [D] . Deane, Susan. 2016

机译：虚拟临床模拟对临床护理技能实施的可转移性的有效性：定性访谈研究。
6. Effectiveness and Safety of Sofosbuvir-Based Regimens for Chronic HCV Genotype 3 Infection: Results of the HCV-TARGET Study [O] . Jordan J. Feld, Raoel Maan, Stefan Zeuzem, -1

机译：基于Sofosbuvir的方案对慢性HCV基因型3感染的有效性和安全性：HCV-TARGET研究的结果
7. Effectiveness of Simeprevir Plus Sofosbuvir, With or Without Ribavirin, in Real-World Patients With HCV Genotype 1 Infection [O] . Johns Hopkins University School of Medicine, Baltimore, Maryland ( host institution ), Afdhal, N. ( author ), Alam, I. ( author ), 2016

机译：Simeprevir加Sofosbuvir联合利巴韦林或不联合利巴韦林对现实世界中HCV基因型1感染患者的有效性

Original article: Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world clinical practice HCV-TARGET study

摘要

著录项

相似文献

相关主题

期刊订阅